
Tiziana Life Sciences PLC TLSA
€ 0.57
-7.35%
Tiziana Life Sciences PLC Betriebsaufwand | TLSA
Betriebsaufwand Jährlich Tiziana Life Sciences PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.8 M | 18 M | 14.6 M | 27.4 M | - | - | - | - | - | - | - | 289 K | 263 K | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 27.4 M | 263 K | 12.7 M |
Betriebsaufwand Vierteljährlich Tiziana Life Sciences PLC
| 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.8 M | 18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 18 M | 15.8 M | 16.9 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Infinity Pharmaceuticals
INFI
|
47.4 M | - | -46.98 % | $ 3.57 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Evelo Biosciences
EVLO
|
108 M | - | -14.46 % | $ 27.9 M | ||
|
Morphic Holding
MORF
|
64 M | - | - | $ 2.42 B | ||
|
Genocea Biosciences
GNCA
|
53.7 M | - | -15.0 % | $ 3.04 M | ||
|
Biogen
BIIB
|
7.49 B | $ 249.55 | 0.98 % | $ 36.6 B | ||
|
Bristol-Myers Squibb Company
BMY
|
34.3 B | $ 58.74 | 0.69 % | $ 119 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
62.1 M | - | -9.21 % | $ 2.55 M | ||
|
IGM Biosciences
IGMS
|
211 M | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
2.04 M | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
178 M | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
772 M | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
10.6 M | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | ||
|
Orchard Therapeutics plc
ORTX
|
159 M | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
61.4 M | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
120 M | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
95.1 M | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
185 M | - | - | $ 2.6 B | ||
|
Syros Pharmaceuticals
SYRS
|
139 M | - | -8.44 % | $ 3.4 M | ||
|
NanoViricides
NNVC
|
8.31 M | $ 1.15 | -2.54 % | $ 23.2 M | ||
|
GT Biopharma
GTBP
|
13.6 M | $ 2.93 | -7.86 % | $ 16.2 M | ||
|
Zymeworks
ZYME
|
53.2 M | $ 26.41 | -1.68 % | $ 1.36 B | ||
|
Aldeyra Therapeutics
ALDX
|
60.1 M | $ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
38.5 M | $ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
700 M | $ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
153 M | $ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
86.4 M | $ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
1.36 B | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
50.9 M | $ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
49.6 M | $ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
1.03 B | $ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
431 M | $ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
11.7 M | $ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
72.9 M | $ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
-35.9 M | $ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
209 M | $ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
94.5 M | $ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
20.7 M | $ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
761 M | $ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
43.9 M | $ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
250 M | $ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
181 M | $ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
758 M | $ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
1 B | $ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
515 M | $ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
320 M | $ 2.89 | -5.25 % | $ 200 M |